ReviewNature reviews. Clinical oncology2018
Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm.
Review in Nature reviews. Clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia.Investigational new drugs · 2024Article
- Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study.Leukemia · 2024Article
- Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia.Bone marrow transplantation · 2024Article
- Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort.Lancet (London, England) · 2023Article
- Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia.Blood · 2022Article
- Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy.Nature reviews. Clinical oncology · 2021Article
- Biological basis for novel mesothelioma therapies.British journal of cancer · 2021Review
- Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse.Blood advances · 2021Article
- Targeting loss of heterozygosity for cancer-specific immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.Nature cancer · 2021Article
- Daily text message assessments of 6-mercaptopurine adherence and its proximal contexts in adolescents and young adults with leukemia: A pilot study.Pediatric blood & cancer · 2021Article
- Microrandomized trials for promoting engagement in mobile health data collection: Adolescent/young adult oral chemotherapy adherence as an example.Current opinion in systems biology · 2020Article
- First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.Journal for immunotherapy of cancer · 2020Article
- Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date.Therapeutics and clinical risk management · 2020Review
- CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.Blood advances · 2019Article
- Targeting the bone marrow microenvironment: a novel therapeutic strategy for pre-B acute lymphoblastic leukemia.Oncotarget · 2019Article
- Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.The Lancet. Oncology · 2019Review
- The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer.Frontiers in immunology · 2019Review
- Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.Expert review of anticancer therapy · 2018Review
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.Journal of hematology & oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29255238What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.